NEWS
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
Delcath Systems, Inc. (Nasdaq: DCTH) announced positive outcomes from an independent study on hepatic perfusion for uveal melanoma patients. The study, conducted by researchers at Moffitt Cancer Center, compared Delcath's HEPZATO KIT™ to immunotherapy and other liver-directed therapies. Key findings include:
1. Overall Survival (OS): Median OS of 22.4 months for first-line therapy and 18.4 months for second-line therapy with HEPZATO KIT.
2. Hepatic Progression-Free Survival (hPFS): First-line HEPZATO KIT showed 17.6 months median hPFS, outperforming immunotherapy (8.8 months) and other therapies (9.2 months).
3. Progression-Free Survival (PFS): First-line HEPZATO KIT demonstrated 15.4 months median PFS, surpassing immunotherapy and other therapies.
The study suggests HEPZATO KIT provides better disease control and improved progression-free survival for patients with hepatic metastases from uveal melanoma.
1. Overall Survival (OS): Median OS of 22.4 months for first-line therapy and 18.4 months for second-line therapy with HEPZATO KIT.
2. Hepatic Progression-Free Survival (hPFS): First-line HEPZATO KIT showed 17.6 months median hPFS, outperforming immunotherapy (8.8 months) and other therapies (9.2 months).
3. Progression-Free Survival (PFS): First-line HEPZATO KIT demonstrated 15.4 months median PFS, surpassing immunotherapy and other therapies.
The study suggests HEPZATO KIT provides better disease control and improved progression-free survival for patients with hepatic metastases from uveal melanoma.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1680Followers
93Following
13KVisitors
Follow